Modality
siRNA
MOA
KRASG12Ci
Target
Aβ
Pathway
Fibrosis
Psoriasis
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ Jul 2028
Phase 3Current
NCT03097479
2,541 pts·Psoriasis
2019-01→2028-07·Terminated
NCT03227659
2,308 pts·Psoriasis
2020-02→TBD·Not yet recruiting
NCT04688187
2,470 pts·Psoriasis
2023-04→2028-02·Active
+1 more trial
8,714 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-12-014mo agoFast Track· Psoriasis
2028-02-011.8y awayPh3 Readout· Psoriasis
2028-07-062.3y awayPh3 Readout· Psoriasis
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Recruit…
P3
Termina…
P3
Not yet…
P3
Active
Catalysts
Fast Track
2025-12-01 · 4mo ago
Psoriasis
Ph3 Readout
2028-02-01 · 1.8y away
Psoriasis
Ph3 Readout
2028-07-06 · 2.3y away
Psoriasis
RecruitingActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03097479 | Phase 3 | Psoriasis | Terminated | 2541 | Mayo |
| NCT03227659 | Phase 3 | Psoriasis | Not yet recr... | 2308 | EFS |
| NCT04688187 | Phase 3 | Psoriasis | Active | 2470 | eGFR |
| NCT08565171 | Phase 3 | Psoriasis | Recruiting | 1395 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ |